Evidence map›Paper›PMID 42690439›Full record

ArticleActa neuropathologica2026

Changes in five cerebrospinal fluid and three plasma Alzheimer's disease biomarkers across increasing brain amyloid-beta and tau pathology burden.

Andrea Mastrangelo, Simone Baiardi, Edoardo Ruggeri, Giuseppe Mario Bentivenga, Claudia Marina Vargiu, Angela Mammana, Marco Sbriccoli, Barbara Polischi, Benedetta Carlà, Sabina Capellari and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea MastrangeloDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Simone BaiardiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Edoardo RuggeriIRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Giuseppe Mario BentivengaDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Claudia Marina VargiuIRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Angela MammanaIRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Marco SbriccoliDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Barbara PolischiIRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Benedetta CarlàIRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Sabina CapellariDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Piero ParchiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. piero.parchi@unibo.it.ORCID https://orcid.org/0000-0002-9444-9524

Funding

Ministero della Salute Ricerca Finalizzata-2021-12374386
6 · The paper itself

Abstract

Neuropathological validation studies of pathology-specific biomarkers for neurodegenerative diseases are essential but are often limited by long sampling-to-death intervals and the lack of semi-quantitative pathology measures. We assessed the associations of five cerebrospinal fluid (CSF) (Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBraintau ProteinsAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAutopsyDiagnosisNeurodegenerative diseasesNeuropathologyStagingValidation

Identifiers

PMID42690439
PMCPMC13541809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.